- Home
- BKYI vs CHEK Comparison
BKYI vs CHEK Comparison
Compare BKYI & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- CHEK
- Stock Information
- Founded
- BKYI 1993
- CHEK 2004
- Country
- BKYI United States
- CHEK Israel
- Employees
- BKYI N/A
- CHEK N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- CHEK Medical Electronics
- Sector
- BKYI Technology
- CHEK Health Care
- Exchange
- BKYI Nasdaq
- CHEK Nasdaq
- Market Cap
- BKYI 4.9M
- CHEK 4.0M
- IPO Year
- BKYI 1997
- CHEK 2015
- Fundamental
- Price
- BKYI $0.85
- CHEK $0.80
- Analyst Decision
- BKYI
- CHEK
- Analyst Count
- BKYI 0
- CHEK 0
- Target Price
- BKYI N/A
- CHEK N/A
- AVG Volume (30 Days)
- BKYI 305.4K
- CHEK 125.3K
- Earning Date
- BKYI 05-15-2025
- CHEK 06-17-2025
- Dividend Yield
- BKYI N/A
- CHEK N/A
- EPS Growth
- BKYI N/A
- CHEK N/A
- EPS
- BKYI N/A
- CHEK N/A
- Revenue
- BKYI $6,355,527.00
- CHEK N/A
- Revenue This Year
- BKYI $7.45
- CHEK N/A
- Revenue Next Year
- BKYI $23.29
- CHEK N/A
- P/E Ratio
- BKYI N/A
- CHEK N/A
- Revenue Growth
- BKYI N/A
- CHEK N/A
- 52 Week Low
- BKYI $0.52
- CHEK $0.56
- 52 Week High
- BKYI $3.68
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- BKYI 57.19
- CHEK 46.52
- Support Level
- BKYI $0.80
- CHEK $0.78
- Resistance Level
- BKYI $0.92
- CHEK $0.86
- Average True Range (ATR)
- BKYI 0.08
- CHEK 0.04
- MACD
- BKYI 0.00
- CHEK -0.01
- Stochastic Oscillator
- BKYI 52.40
- CHEK 15.73
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.